Synthetic graft

Synthetic grafts are fabricated from engineered materials such as polytetrafluoroethylene (PTFE), polyethylene terephthalate (PET/Dacron), polyglycolic acid (PGA), polylactic acid (PLA), carbon fiber composites, or calcium phosphate ceramics. The specific material chosen depends on the mechanical demands of the target tissue—high-tensile polymers for ligament reconstruction, osteoconductive ceramics for bone void filling. Because the material is manufactured rather than harvested, surgeons can specify geometry, porosity, and degradation profile before the procedure.

In orthopedic practice, synthetic grafts appear across a wide range of procedures: anterior cruciate ligament (ACL) reconstruction (when autograft or allograft is unavailable or declined), bone-void filling after tumor excision or fracture fixation, rotator cuff augmentation, and tendon bridging. Resorbable variants are gradually replaced by host tissue over weeks to months; non-resorbable variants remain permanently in situ. The clinical rationale for choosing synthetic over biologic graft material typically centers on patient factors such as age, infection risk, prior failed biologic graft, or inventory constraints at the surgical facility.

From a payer perspective, synthetic grafts occupy a distinct coding space. HCPCS code C1763 (Connective tissue, non-human, includes synthetic) is the primary supply code used in hospital outpatient and ambulatory surgical center (ASC) settings. Separately, bone-graft substitute CPT codes (e.g., 20930–20938) may apply depending on graft type and surgical context. The NCCI Policy Manual (Chapter IV, musculoskeletal system) makes clear that graft procurement or supply codes are not separately billable when the graft work is already captured within the descriptor of the primary procedure code—a rule that applies to synthetic grafts just as it does to biologic ones.

Misclassifying a synthetic graft as an allograft or autograft on a claim creates a direct audit and denial risk. Payers—including Medicare contractors operating under NCCI edits—distinguish graft types because reimbursement pathways differ: supply codes such as C1763 apply only to non-human or synthetic materials, while autograft procurement carries separate CPT codes with distinct RVUs. Billing a synthetic graft under an autograft CPT code inflates the RVU count and can trigger a Medically Unlikely Edit (MUE) flag or a post-payment medical review. Conversely, failing to bill C1763 in an ASC or HOPD setting forfeits a legitimate implant passthrough payment. Getting the graft type right at the documentation level—specifically recording 'synthetic' or naming the material in the operative note—is the single most important step to clean claim submission.